Q2 2021 BioArctic AB Earnings Call Transcript
Welcome to the BioArctic Q2 Report 2021. Today, I am pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. (Operator Instructions) Speakers, please begin.
()-
Thank you so much. Most welcome to BioArctic's Second Quarter Report for 2021. I'm Gunilla Osswald, and I'm the CEO of BioArctic and I will share the presentation here today with our CFO, Jan Mattsson.
I think it's exciting times for the Alzheimer's community now, both regarding diagnostics with progress of blood biomarkers and also with new therapies. We are most likely on our way towards a paradigm shift for the treatment of Alzheimer's disease. And our most advanced program, lecanemab, previously called BAN2401, was granted breakthrough therapy designation by the FDA in late June. And I will describe more about that in the presentation here today.
Next slide, please. BioArctic is listed on Nasdaq Stockholm Mid-Cap, and this is our disclaimer.
Next slide, please. BioArctic is a unique Swedish
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |